The impact of UV360 on the viability and developmental progression of zebrafish embryos. حسب Lihan Xu (18778257)

General procedure for the synthesis of A and A-c1. حسب Xueqin lu (22250795)

The Laboratory Animal Flow Diagram. حسب Xueqin lu (22250795)

"…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …"

¹H NMR spectra for kylo-0603. حسب Xueqin lu (22250795)

"…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …"

¹³C NMR spectra for Kylo-0603. حسب Xueqin lu (22250795)

"…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …"

The structures of T3 and Kylo-0603. حسب Xueqin lu (22250795)

"…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …"

Synthesis process of Kylo-0603. حسب Xueqin lu (22250795)

"…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …"

ESI-HRMS spectra for Kylo-0603. حسب Xueqin lu (22250795)

"…The non-alcoholic steatohepatitis (NASH) activity score (NAS) demonstrated a significant reduction of up to 3.7 points (P < 0.0001), while the fibrosis score decreased by 0.6 points (P < 0.05). …"

Effects of Kylo-0603 on the expression of related genes of the MASH mouse models. حسب Xueqin lu (22250795)

General procedure for the synthesis of B. حسب Xueqin lu (22250795)

Effects of Kylo-0603 on body weight, organ weight, and body fat content. حسب Xueqin lu (22250795)

The body weight and cholesterol levels of the mice were recorded before the administration of the drug. حسب Xueqin lu (22250795)

The trends of cholesterol metabolism-related gene expression in liver tissue. حسب Xueqin lu (22250795)

Kylo-0603’s EC50 & tissue levels. حسب Xueqin lu (22250795)

DIO Mice Liver Staining. حسب Xueqin lu (22250795)

The Fibrosis scoring by Sirius Red staining and SHG/TPEF. حسب Xueqin lu (22250795)

Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). حسب Xueqin lu (22250795)

After 8 weeks of treatment, body fat analysis and bone mineral density testing of mice in each group. حسب Xueqin lu (22250795)

Plasma cholesterol and LDL-C levels. حسب Xueqin lu (22250795)

The Chol and TG content in liver homogenates of the mice in each group after 2 and 10 weeks of drug intervention. حسب Xueqin lu (22250795)